ReviewJournal of natural products2026
The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives.
Review in Journal of natural products, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Integrating biomass production platform and identification approach for stereochemical assignment of super-carbon-chain compounds.Science advances · 2026Article
- Article
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Biosynthesis of O-Prenylated Chaetophenols Triggers Nonenzymatic Pathways toward Structural Diversity.Organic letters · 2026Article
- Exploring the Anti-Inflammatory Potential ofPlants (Basel, Switzerland) · 2026Article
- Highly stereoselective synthesis of complex moleculesRSC advances · 2026Article
- High side chain promiscuity of the terminal enzyme in the homologation pathway for l-phenylalanine and l-tyrosine.bioRxiv : the preprint server for biology · 2026Article
- Article
- Bridging Two Worlds: Structural and Pharmacological Aspects of Natural Triterpenoid Dimers: Pristimerin-Pristimerin-Type Dimers.Molecules (Basel, Switzerland) · 2026Review
- Diels-Alder Adducts fromInternational journal of molecular sciences · 2026Article
- Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associatedmSystems · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Natural products (NPs) have long played a pivotal role in medicine, serving as both lead compounds and approved drugs in diverse therapeutic areas. Inspired by the 2004 review "The Role of Natural Product Chemistry in Drug Discovery", we adopted a data-driven approach to assess the current role of NPs in drug discovery. We identified 119 NP-derived (NP-D) drugs, including 16 antibody-drug conjugates (ADCs), that were first approved globally between January 2000 and September 2025. Their development timelines, source organisms, manufacturing methods, indications, and routes of administration were analyzed. Six NP-D case studies illustrating successful progression from discovery to clinical use were highlighted: omaveloxolone (novel pharmacology, first-in-class), fidaxomicin, ibrexafungerp, epoxomicin, eribulin (known pharmacology, new drug class), and the gliflozin drug family (13 members). We also examined the presence and sales of NP-D agents among the top 200 brand name drugs in 2006, 2015, and 2024. Although overall NP-D drug sales have declined, dapagliflozin and empagliflozin demonstrate that blockbuster status is still achievable. While growth is modest, NPs remain highly valuable active pharmaceutical ingredients (APIs) with substantial clinical impact. Significant opportunities persist for drug-focused NP R&D efforts, as many recently validated therapeutic targets remain underexplored for NP-D chemotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.